Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Healthcare Triangle (HCTI) Total Non-Current Liabilities (2021 - 2025)

Healthcare Triangle filings provide 5 years of Total Non-Current Liabilities readings, the most recent being $3.9 million for Q3 2025.

  • On a quarterly basis, Total Non-Current Liabilities fell 35.7% to $3.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.9 million, a 35.7% decrease, with the full-year FY2024 number at $6.6 million, down 15.15% from a year prior.
  • Total Non-Current Liabilities reached $3.9 million in Q3 2025 per HCTI's latest filing, up from $3.2 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $9.5 million in Q1 2023, with the low at $3.2 million in Q2 2025.
  • A 5-year average of $6.8 million and a median of $6.9 million in 2024 define the central range for Total Non-Current Liabilities.
  • Year-over-year, Total Non-Current Liabilities grew 23.75% in 2023 and then tumbled 48.78% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $6.3 million in 2021, then increased by 5.54% to $6.6 million in 2022, then increased by 17.46% to $7.7 million in 2023, then fell by 15.15% to $6.6 million in 2024, then tumbled by 40.5% to $3.9 million in 2025.
  • Per Business Quant, the three most recent readings for HCTI's Total Non-Current Liabilities are $3.9 million (Q3 2025), $3.2 million (Q2 2025), and $6.6 million (Q4 2024).